ad image

Company Info

Gilead Sciences

Gilead Sciences

Drug Discovery & Development

Overview

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it’s estimated that more than 10 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.

Gilead Sciences
Contributions
19 Contributions1 / 1
Gilead Sciences
M&A

Gilead Sciences to Acquire Immunomedics

Gilead Sciences

PR-M09-20-NI-18Sep 15, 2020
Gilead Sciences
COVID-19

Gilead’s Remdesivir Receives FDA Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19

Gilead Sciences

PR-M08-20-NI-48Aug 31, 2020
Gilead Sciences
Strategic Partnership

Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies

Gilead Sciences

PR-M07-20-NI-021Jul 15, 2020
Gilead Sciences
COVID-19 Trial Data

Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19

Gilead Sciences

PR-M07-20-NI-015Jul 10, 2020
Gilead Sciences
M&A

Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

Gilead Sciences

PR-M06-20-NI-028Jun 23, 2020
Gilead Sciences
Partnership

Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies

Gilead Sciences

PR-M05-20-NI-041May 28, 2020
Gilead Sciences

Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials

Gilead Sciences

PR-M04-20-NI-003Apr 02, 2020
Gilead Sciences
M&A

Gilead to Acquire Forty Seven for $4.9 Billion

Gilead Sciences

PR-M03-20-NI-003Mar 02, 2020
Gilead Sciences
Coronavirus

Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19

Gilead Sciences

PR-M02-20-NI-037Feb 27, 2020
Gilead Sciences
Coronavirus

Gilead Sciences Begins Trial on Treatment for Coronavirus (2019-nCoV)

Gilead Sciences

PR-M02-20-NI-003Feb 04, 2020
Gilead Sciences
Clinical Trials

Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis

Gilead Sciences

PR-M10-19-NI-017Oct 11, 2019
Gilead Sciences
Collaboration

Gilead and Galapagos Enter Into Transformative Research and Development Collaboration

Gilead Sciences

PR-M07-19-NI-046Jul 18, 2019
Gilead Sciences
Capacity Expansion

Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility

Gilead Sciences

PR-M07-19-NI-043Jul 17, 2019
Gilead Sciences
Appointment

Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer

Gilead Sciences

PR-M05-19-NI-081May 29, 2019
Gilead Sciences
HIV

Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic

Gilead Sciences

PR-M05-19-NI-038May 14, 2019
Gilead Sciences
HIV Diagnoses

Gilead Announces New Data on the Impact of Truvada® for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States

Gilead Sciences

PR-M07-18-NI-087Jul 26, 2018
Gilead Sciences
FDA Approval

U.S. Food and Drug Administration Approves Expanded Indication for Truvada®

Gilead Sciences

PR-M05-18-NI-073May 18, 2018
Gilead Sciences

Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope

Gilead Sciences

PR-M03-18-NI-021Mar 06, 2018
Gilead Sciences
Appointment

Gilead Sciences Announces Senior Management Change

Gilead Sciences

PR-M02-18-NI-101Feb 27, 2018
1 / 1
0 Contributors1 / 0

No authors found

1 / 0